CAR-T therapies

News

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

Kelonia only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but will report impressive results at ASH next month.

News

After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.

News

There is enough experience with the first wave of autologous CAR-T therapies to allow strict rules ensuring their safe use to be relaxed, says FDA.

News

Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.

News

Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.